Indoximod Combo Shows Survival Gains in Ependymoma
Interim phase 2 data from Augusta University researchers link immune T-cell expansion to longer survival in recurrent ependymoma patients.
Updated on Nov. 14, 2026 in Cancer

Augusta University researchers presented interim phase 2 trial data on oral indoximod plus temozolomide in recurrent ependymoma at the 2026 SNO Annual Meeting. Patients with high T-cell clonal expansion showed longer median overall survival than those with low expansion.
Why it matters
Recurrent ependymoma has limited treatment options, and the trial's subgroup analysis suggests immune activity may help identify patients who respond better. The findings are interim and drawn from a small number of patients, so they do not yet establish a clinical standard.
The interim analysis covers 54 ependymoma patients with an estimated median overall survival of 23.8 months, and in a 51-patient training set the high clonal expansion group reached 26.3 months versus 7.6 months for the low group. The sample sizes are small and final trial outcomes have not yet been reported.
The players
Augusta University
Augusta University is a public research university in Augusta, Georgia, with medical and research programs in oncology and neuroscience.
Wellstar Health System
Wellstar Health System is a nonprofit health system based in Georgia that operates hospitals and clinical care services across the Atlanta region and beyond.
The details
The trial, registered as NCT04049669, combines oral indoximod with temozolomide in patients with recurrent ependymoma. Researchers combined single-cell T-cell receptor sequencing with single-cell RNA sequencing on patients' blood to measure immune responses, and more than half of patients showed T-cell clonal expansion.
Timeline
2026: Interim data presented at the SNO Annual Meeting
Health Landscape
The findings extend the indoximod clinical development program, which tests whether blocking the IDO pathway can restore immune responses to tumor cells when combined with chemotherapy. Ependymoma remains a rare tumor with few treatment options after recurrence, so the immune-marker approach is being examined as a way to sort patients by likely benefit.
For patients with recurrent ependymoma, the results point toward immune-marker testing as a possible way to identify who may benefit from the indoximod combination. Any access to the therapy would depend on trial enrollment or future approval, which the interim data do not guarantee.
The takeaway
Immune-response measurements taken from blood may eventually help clinicians decide which ependymoma patients are most likely to benefit from a targeted combination. Readers should treat these interim, small-sample findings as early evidence rather than settled practice.
Further reading
Explore more Cancer research and treatment news.
Source note: This article includes information reported by OncLive.










